New personalized cell therapy targets tough cancers in early trial
NCT ID NCT07196579
First seen Sep 30, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This early-phase study tests a personalized treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer. The main goals are to check safety and find the right dose, with 30 participants expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.